Key result
Prasugrel monotherapy post-PCI for CCS appears safe with a ~0.2% major event rate at 3 months.
Why the study?
This comparative analysis of the 2 ASET pilot studies aimed to summarize clinical outcomes and assess geographic and ethnic differences in baseline demographics and procedures with prasugrel monotherapy without aspirin immediately after PCI.
Does prasugrel monotherapy without aspirin immediately after PCI prevent ischemic and bleeding events in patients with chronic coronary syndrome?
Observational (n=409)
Yes
Does prasugrel monotherapy without aspirin immediately after PCI prevent ischemic and bleeding events in patients with chronic coronary syndrome?
Prasugrel monotherapy immediately after PCI appears safe and feasible in selected low-risk patients with chronic coronary syndrome.
Answers are grounded in this paper and cite their sources.
Supports feasibility of prasugrel monotherapy post-PCI in low-risk CCS; leaves open confirmation versus DAPT in randomized trials.
The ASET (Acetyl-Salicylic Elimination Trial) pilot studies recently investigated P2Y12 inhibitor monotherapy without aspirin immediately after percutaneous coronary intervention (PCI) in Brazil and Japan. This comparative analysis of the 2 ASET pilot studies aimed to summarize clinical outcomes and assess geographic and ethnic differences in baseline demographics and procedures. Patients undergoing successful platinum-chromium everolimus-eluting stent implantation for chronic coronary syndrome were included. Following the index PCI, patients received prasugrel monotherapy with a maintenance dose of 10 mg/day in Brazil and 3.75 mg/day in Japan. The primary ischemic endpoint was the composite of cardiac death, spontaneous target vessel myocardial infarction, or definite stent thrombosis. The primary bleeding endpoint was Bleeding Academic Research Consortium types 3 and 5 bleeding at up to 3 months. Of 409 enrollments, 3-month follow-up was completed in 406 patients. Mean age was 64.3 ± 8.4 years, and 73% were men. Overall, post-TIMI flow grade 3 was achieved in 99.8%. Intravascular imaging for poststent optimization was used in 16.8% and 99.6% of treated lesions in Brazil and Japan, respectively. The primary ischemic and bleeding endpoints occurred in the same patient (0.2%). No stent thrombosis events occurred. Prasugrel monotherapy following PCI was safe and feasible in selected low-risk chronic coronary syndrome patients after optimal platinum-chromium everolimus-eluting stent implantation regardless of the ethnic and geographic differences in baseline demographics, procedures, and prasugrel dosage. Randomized controlled trials will be needed to compare P2Y12 inhibitor monotherapy without aspirin with the current standard of care.
No takes yet. Share an insight, caveat, or question.
Masuda et al. (2023) conducted an observational in Chronic coronary syndrome (n=409). Prasugrel monotherapy was evaluated on Composite of cardiac death, spontaneous target vessel myocardial infarction, or definite stent thrombosis (ischemic); and BARC types 3 and 5 bleeding (bleeding). Prasugrel monotherapy immediately after PCI for chronic coronary syndrome was safe and feasible, with primary ischemic and bleeding endpoints occurring in only 0.2% of patients at 3 months.
Synapse has enriched 10 related papers. Consider them for comparative context: